Leanerships

Applications Open for the Lancet Laboratories Phlebotomy Learnership Programme 2022

Applications Open for the Lancet Laboratories Phlebotomy Learnership Programme 2022. An opportunity has presented itself to appoint a suitably qualified candidate into the position of Student Phlebotomy Technician. This is a Phlebotomy learnership position based at Gauteng, Limpopo, Northwest, KwaZulu Natal and Mpumalanga.

Role Purpose:

To develop learner competence (i.e. broad knowledge, skills and values) in performing phlebotomy techniques within a medical pathology environment.

Responsibilities:

  • A Phlebotomy Technician is trained to draw blood and collect specimens from patient or donors.
  • Phlebotomy learners attend structured learning programmes including theory and practical training.
  • Attends formal training programme including lectures, practical training and submission of assignments.
  • Writing of Health Professions Council (HPCSA) board examination.
  • Meet contractual obligations of Learnership appointment.
  • Collection of venous and capillary blood and non-blood specimens for medical and blood donation purposes.
  • Implements sound housekeeping procedures in accordance with relevant legislation and all safety protocols.
  • Represents the organization by applying the principles of customer care.

Requirements:

  • Grade 12 with English, Mathematics and Biology D symbol
  • 0-1 Yrs Relevant Working Experience

After successful completion of the 24 month training programme and the HPCSA board examination, the learner will be able to register with the HPCSA as a qualified Phlebotomy Technician enabling them to be employed in Medical pathology laboratories and blood donation organisations.

How to Apply

Location: Gauteng, Limpopo, Northwest and Mpumalanga

Apply Online for the Lancet Laboratories: Phlebotomy Learnership Programme 2022 / 2023


Location: KwaZulu Natal

Apply Online for the Lancet Laboratories: Phlebotomy Learnership Programme 2022 / 2023

Closing Date: Friday 26th August 2022

Related Articles

Back to top button

Adblock Detected

Please turn off your ad blocker first to read this article